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Summary
Background.  —  Chronic  obstructive  pulmonary  disease  (COPD)  and  cardiovascular  diseases  (CVD)
share risk  factors  and  impair  each  other’s  prognosis.
Aims.  —  To  assess  the  prevalence  of  airﬂow  limitation  (AL)  compatible  with  COPD  in  a  population
at cardiovascular  risk  and  to  identify  determinants  of  AL.
Methods.  —  All  consecutive  patients  referred  to  the  cardiovascular  prevention  unit  of  a  univer-
sity hospital  in  2009  were  studied  in  a  cross-sectional  analysis.  Patients  answered  questionnaires
on socioeconomic  status,  medical  history  and  lifestyle,  and  underwent  extensive  physical  exami-
nations, biological  measures  and  spirometry  testing.  AL  was  deﬁned  as  FEV1/FVC  <  0.70,  without
any history  of  asthma.  Determinants  of  AL  were  assessed  using  logistic  regression.
Results.  —  The  sample  comprised  493  participants  (mean  age  57.4  ±  11.1  years);  60%  were  men,
18% were  current  smokers,  42%  were  ex-smokers  and  10%  of  patients  had  a  history  of  CVD.
Abbreviations: AL, airﬂow limitation; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular
disease; FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity; LDL-C, low-density lipoprotein cholesterol.
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Ten-year  risk  of  coronary  heart  disease  (CHD)  according  to  the  Framingham  equation  was  inter-
mediate  (10—20%)  for  25%  of  patients  and  high  (>  20%)  for  10%.  Prevalence  of  AL  was  5.9%  (95%
conﬁdence  interval  [CI]  4.0—8.3%)  in  the  whole  population  and  4.3%  (2.6—6.6%)  among  subjects
in primary  cardiovascular  prevention.  AL  was  independently  associated  with  CVD  (adjusted  odds
ratio 4.18,  95%  CI  1.72—10.15;  P  =  0.002)  but  not  with  Framingham  CHD  risk.  More  than  80%  of
patients screened  with  AL  had  not  been  diagnosed  previously  and  more  than  one  in  two  patients
was asymptomatic.
Conclusion.  —  Patients  with  CVD  are  at  increased  risk  of  AL  and  thus  should  beneﬁt  from  AL
screening as  they  are  frequently  asymptomatic.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  broncho-pneumopathie  chronique  ostructive  (BPCO)  et  les  maladies  cardiovas-
culaires  (CV)  présentent  des  facteurs  de  risques  communs  et  leur  association  chez  un  même
patient grève  le  pronostic.
L’objectif.  — A  été  d’évaluer  la  prévalence  des  troubles  ventilatoires  obstructifs  (TVO)  dans
une population  à  risque  CV  et  d’analyser  les  déterminants  de  l’obstruction  bronchique.
Méthodes.  — Notre  étude  est  basée  sur  les  patients  adressés  au  centre  de  détection  et  de
prévention de  l’athérosclérose  du  CHU  de  Toulouse  en  2009.  Les  participants  ont  répondu  à
un questionnaire  évaluant  le  niveau  socioéconomique,  les  antécédents  médicaux  et  le  style  de
vie. Ils  ont  bénéﬁcié  d’un  examen  clinique  et  d’une  spirométrie.  Un  TVO  était  diagnostiqué
si VEMS/CV  était  inférieur  à  0,70  sans  antécédent  d’asthme.  Les  déterminants  du  TVO  ont  été
évalués par  régression  logistique.
Résultats.  —  L’échantillon  comprend  493  participants  (âge  moyen  :  57,4  ±  11,1  ans),  dont  60  %
d’hommes,  18  %  des  fumeurs  actuels,  42  %  d’anciens  fumeurs  et  10  %  de  sujets  atteints  de  mal-
adies CV.  Le  risque  de  maladie  coronarienne  à  dix  ans  selon  l’équation  de  Framingham  était
intermédiaire  (10—20  %)  pour  25  %  des  sujets  et  élevé  (>  20  %)  pour  10  %.  La  prévalence  des
TVO était  de  5,9  %  [IC95  %  :  4,0—8,3  %]  (4,3  %  [IC95  %  :  2,6  %—6,6  %]  chez  les  sujets  en  préven-
tion CV  primaire).  Le  TVO  était  indépendamment  associé  aux  maladies  CV  (OR  ajusté  =  4,18
[1,72—10,15]  ;  p  =  0,002)  mais  pas  au  score  de  Framingham.  Plus  de  80  %  des  patients  dépistés
avec un  TVO  n’en  avaient  pas  connaissance  et  un  patient  sur  deux  était  asymptomatique.
Conclusion.  —  Les  patients  atteints  de  maladies  CV  ont  un  risque  accru  de  BPCO  qui  est  souvent
asymptomatique.  Ils  devraient  donc  bénéﬁcier  d’un  dépistage  spirométrique.
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An  extensive  questionnaire,  derived  from  the  questionnaire
used  in  the  French  MONICA  (monitoring  trends  and  deter-© 2011  Elsevier  Masson  SAS
ntroduction
OPD  affects  approximately  7.5%  of  the  adult  population.
y  2020,  COPD  is  expected  to  be  the  third  most  common
ause  of  death  and  the  ﬁfth  most  common  cause  of  dis-
bility  in  the  world  [1,2]. Paradoxically,  this  disease  is
idely  under-diagnosed  [3],  in  part  because  symptoms
ppear  progressively  and  become  obvious  only  when  lung
unction  is  already  signiﬁcantly  impaired  [4].  Besides,  COPD
s  strongly  associated  with  CVD  [5—9]  and,  among  subjects
ith  CVD,  the  coexistence  of  COPD  is  associated  with  a
aised  morbidity  including  more  frequent  hospitalizations
nd  worsening  of  symptoms  [9—11]. In  addition,  cardiovas-
ular  deaths  account  for  a  signiﬁcant  part  of  the  mortality
n  COPD  patients.
COPD  prevalence  has  been  estimated  in  several  studies
mong  patients  with  CVD  [12—15], but  remains  unknown  in
symptomatic  subjects  at  cardiovascular  risk  for  whom  the
ombination  with  COPD  may  worsen  prognosis  [9].  Such  a
ituation  should  be  avoided  today  as  COPD  is  now  considered
s  a  preventable  and  treatable  disease  [16—18].
The  aim  of  this  study  was  to  assess  the  prevalence  of
L  in  a  population  at  cardiovascular  risk  and  to  identify
eterminants  of  AL  in  this  population. ms  droits  réservés.
ethods
atients
his  report  is  based  on  a  cross-sectional  study  comprising
19  consecutive  subjects  referred  to  a  preventive  cardiol-
gy  unit  in  a  French  university  hospital  between  January
009  and  January  2010.  Patients  were  either  self-referred
r  referred  by  their  primary  care  physician  or  cardiologist
or  cardiovascular  risk  assessment,  management  of  risk  fac-
ors  and  routine  ambulatory  screening  for  CVD.  All  of  the
atients  were  invited  to  participate  in  the  study;  502  (97%)
ccepted.  The  study  was  approved  by  the  appropriate  ethics
ommittee,  in  accordance  with  French  law  (Comité  de  pro-
ection  des  personnes  Sud-Ouest  et  Outre-Mer  II,  number
-08-25)  and  all  participants  signed  an  informed  consent
orm  attesting  they  had  received  information  about  the
tudy  and  agreed  to  participate.
ata collectioninants  in  CVD)  population  surveys  [19]  carried  out  in  the
 risk  
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eUndiagnosed  airﬂow  limitation  in  patients  at  cardiovascular
same  region,  was  administered  to  each  participant  by  a
trained  and  certiﬁed  medical  staff  member.  Data  concerning
socioeconomic  status,  personal  and  family  medical  history
(including  family  history  of  premature  myocardial  infarc-
tion,  i.e.  before  55  years  for  the  father  or  65  years  for  the
mother),  drug  intake,  cardiovascular  risk  factors,  pulmonary
symptoms  (cough,  sputum,  dyspnoea),  lifestyle  and  qual-
ity  of  life  were  recorded.  Educational  level  was  assessed  by
the  level  of  graduation  or  school  dropout.  Smoking  status
was  described  as  never  smoking  (0  pack-years),  past  smok-
ing  (smoking  cessation  ≥  1  year  before  inclusion  in  the  study)
or  current  smoking  (estimated  in  pack-years).  All  subjects
underwent  a  physical  examination,  blood  sample  collection,
electrocardiography,  exercise  test  and  spirometry  test.  A
maximal  exercise  test  was  deﬁned  as  a  peak  heart  rate  ≥  85%
of  the  maximal  predicted  heart  rate  for  a  given  age  [20].
The  exercise  test  was  stopped  when  the  participant  was
unable  to  continue  or  in  the  case  of  electrocardiographic
or  blood  pressure  abnormalities.  Height,  weight  and  arte-
rial  blood  pressure  (mean  of  two  measurements  performed
with  an  automatic  sphygmomanometer  in  a  sitting  position
after  ≥  5  min  of  rest)  were  measured  according  to  standard-
ized  protocols  by  the  medical  staff.  Body  mass  index  was
calculated  as  weight  divided  by  height  squared  (kg/m2).
Dyspnoea  was  quantiﬁed  according  to  the  modiﬁed  Medi-
cal  Research  Council  (MRC)  scale  [21]. Symptoms  of  chronic
bronchitis  were  assessed  using  questions  derived  from  the
European  Community  Respiratory  Health  Survey  [22]. Qual-
ity  of  life  was  measured  by  the  EuroQol  5D  scale  [23].
Blood  samples  were  taken  after  ≥  10  h  of  overnight  fast.
LDL-C  was  determined  by  the  Friedewald  formula  [24].
Diabetes  was  assessed  for  people  with  fasting  blood  glu-
cose  ≥  7  mmol/L  (126  mg/dL)  or  under  hypoglycaemic  drug
treatment.  The  10-year  risk  of  CHD  (hard  event,  i.e.  myocar-
dial  infarction,  coronary  insufﬁciency  or  CHD  death)  was
estimated  with  the  Framingham  equation  (charts  using  LDL-
C  categories)  in  subjects  without  CVD  (i.e.,  ischaemic  heart
disease,  history  of  cerebrovascular  disease  or  atheroscle-
rosis  in  other  arteries  such  as  aorta,  renal  or  lower  limb
arteries)  [25].
Spirometry
Spirometry  was  conducted  according  to  ATS/ERS  guidelines
[26,27]  by  means  of  a  portable  spirometer  (MINISPIR,  MIR
Medical,  Rome,  Italy).  All  spirometric  measurements  were
reviewed  individually  and  graded  for  quality  by  an  experi-
enced  senior  pulmonologist  (R.E.).
AL  compatible  with  COPD  was  deﬁned  according  to  the
Global  initiative  for  Obstructive  Lung  Disease  (GOLD)  guide-
lines  [16], when  forced  expiratory  volume  in  1  s  (FEV1)
divided  by  forced  vital  capacity  (FVC)  was  <  0.70,  without
any  history  of  asthma.  The  severity  of  AL  was  staged  accord-
ing  to  the  GOLD  guidelines  as  mild  (stage  I),  moderate
(stage  II),  severe  (stage  III)  or  very  severe  (stage  IV),  respec-
tively,  for  percent  predicted  FEV1 ≥  80%,  50%  ≤  FEV1  <  80%,
30%  ≤  FEV1  <  50%,  and  FEV1  <  30%  (or  FEV1  <  50%  plus  chronic
respiratory  failure),  respectively.  Because  our  population
was  at  cardiovascular  risk  and  because  a  maximal  stress
test  was  included  in  the  check-up  (performed  on  a  single
day)  [20], postbronchodilator  reversibility  to  beta-2  agonists
could  not  be  tested.
a
C
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tatistical analysis
he  statistical  analysis  was  performed  with  Stata  statistical
oftware  (version  9.2,  STATA  Corporation,  College  station,
X,  USA).  Prevalence  of  AL  is  given  with  95%  conﬁdence
nterval  (CI).  In  bivariate  analysis,  qualitative  variables  were
ompared  with  the  2-test  (or  bilateral  Fisher’s  exact  test,
hen  necessary).  Student’s  t-test  (or  the  Mann-Whitney’s
est  when  the  distribution  of  continuous  variables  was
kewed  or  the  hypothesis  of  homoscedasticity  was  not
espected)  was  used  to  compare  quantitative  data  according
o  categories  of  qualitative  variables.  As  bivariate  analy-
es  were  performed  only  to  screen  variables  that  should
e  introduced  in  multivariable  models,  no  adjustment  for
ultiple  comparisons  was  performed.  Independent  determi-
ants  of  AL  were  assessed  with  logistic  regression.  Variables
ssociated  with  AL  in  bivariate  analysis  (P  <  0.20)  were  intro-
uced  in  the  multivariable  model.  A  backward  procedure
as  applied  to  assess  variables  that  were  signiﬁcantly  and
ndependently  associated  with  AL  (P  <  0.05).  Age  and  smok-
ng  status  were  kept  in  the  model  despite  a  P-value  >  0.05  as
hey  are  well  known  risk  factors  for  AL.
esults
opulation sample
verall,  502  of  the  519  eligible  subjects  (97%)  agreed  to
articipate.  Nine  patients  with  FEV1/FVC  <  0.70  and  a  history
f  asthma  were  excluded  from  the  analysis,  as  asthma  and
OPD  could  not  be  differentiated  in  these  patients  due  to
he  lack  of  reversibility  testing.  Table  1  describes  the  493
atients  at  cardiovascular  risk  enrolled  in  the  study.  Mean
ge  was  57.4  ±  11.1  years.  Of  the  study  population,  60%  were
en,  18%  were  current  smokers,  42%  were  ex-smokers  and
0%  had  CVD.  The  10-year  risk  of  a  CHD  event  (calculated
nly  in  patients  without  CVD),  according  to  the  Framingham
quation  (LDL-C  chart)  [25], was  intermediate  (between  10
nd  20%)  for  25%  of  patients  and  high  (>  20%)  for  10%  of  the
ample.
revalence of airﬂow limitation
 total  of  29  patients  exhibited  AL.  Fig.  1  shows  the  preva-
ence  of  AL  according  to  the  GOLD  classiﬁcation  [16]  and
he  prevalence  of  AL  or  reported  COPD.  The  overall  preva-
ence  of  FEV1/FVC  <  0.70  (AL)  was  5.9%  (95%  CI  4.0—8.3%).
wenty-three  patients  (79.5%)  presented  in  GOLD  stage  I,
7%  (n  =  5)  in  GOLD  stage  II  and  3.5%  (n  =  1)  in  GOLD  stage  III.
one  of  the  AL  patients  reached  stage  IV.  The  prevalence  of
EV1/FVC  <  0.70  without  previously  known  COPD  (screened
L)  was  5.1%  (95%  CI  3.3—7.4%)  (i.e.,  86%  [n  =  25]  of  AL
atients  had  not  been  diagnosed  previously).  The  prevalence
f  FEV1/FVC  <  0.70  or  reported  COPD  (with  FEV1/FVC  ≥  0.70)
as  7.5%  (95%  CI  5.3—10.2%)  (eight  patients  reported  COPD
ut  exhibited  a  normal  FEV1/FVC  ratio).
Among  the  individuals  in  primary  prevention  of  CVD,  19
xhibited  AL:  79%  (n  =  15)  in  stage  I,  16%  (n  =  3)  in  stage  II,
nd  5%  (n  =  1)  in  stage  III.  The  prevalence  of  AL  was  4.3%  (95%
I  2.6—6.6%).  As  in  the  whole  population,  most  patients  with
L  (84%;  n =  16)  had  not  been  diagnosed  previously.
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Table  1  Description  of  the  study  population.
Patients  at
cardiovascular  risk
(n  =  493)
Age  (years) 57.4 ±  11.1
Men  294  (60)
Educational  level  ≥  high  school
completion
285  (58)
Smoking  status
Never  200  (41)
Past  206  (42)
Current  87  (18)
Diabetes  37  (8)
Antihypertensive  drug  treatment 126  (26)
Lipid-lowering  drug  216  (44)
Body  mass  index  (kg/m2)  26  ±  4.6
C-reactive  protein  (mg/L)  2.9  ±  4.6
Family  history  of  premature
myocardial  infarctiona
29  (6)
Framingham  hard  CHD  riskb
<  10%  256  (54)
10—20%  120  (25)
>  20%  49  (10)
History  of  cardiovascular  diseasec 47  (10)
History  of  COPDd 12  (2)
Data are number (%) or mean ± SD. CHD: coronary heart disease;
COPD: chronic obstructive pulmonary disease.
a Family history of premature myocardial infarction, i.e. before
55 years old for the father or 65 for the mother.
b 10-year risk of hard coronary heart disease event according
to the Framingham equation (chart using LDL-cholesterol cat-
egories) [25] in subjects without any history of cardiovascular
disease.
c Ischaemic heart disease, history of cerebrovascular disease,
atherosclerosis in other arteries such as
d Declared or treated COPD.
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Figure 1. Prevalence of airﬂow limitation (AL) according to the
GOLD classiﬁcation [16] and history of Chronic obstructive pul-
monary disease (COPD).
CI: conﬁdence interval; COPD: chronic obstructive pulmonary dis-
ease.
*AL: forced expiratory volume in one second (FEV1)/forced vital
capacity (FVC) < 0.70.
**Screened AL: FEV1/FVC < 0.70 without known COPD.
***AL or history of COPD: FEV1/FVC < 0.70 or history of COPD (with
FEV1/FVC ≥ 0.70).
I: stage I, mild AL (FEV1/FVC < 0.70 and predicted FEV1 ≥ 80%).
II: stage II, moderate AL (FEV1/FVC < 0.70 and 50% ≤ predicted
FEV1 < 80%).
III: stage III, severe AL (FEV1/FVC < 0.70 and 30% ≤ predicted
FEV1 < 50%).
No stage IV was observed in the sample: very severe AL
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taken  into  account  in  prevalence  estimation.  Previously,  theeterminants of airﬂow limitation
able  2  shows  the  main  characteristics  of  AL  and  non-AL  par-
icipants.  Male  gender,  smoking,  lipid-lowering  treatment
nd  presence  of  CVD  were  signiﬁcantly  associated  with  AL
n  bivariate  analyses.  As  expected,  FEV1 and  FEV1/FVC  were
igniﬁcantly  lower  in  the  AL  group.  Subjects  with  AL  had
igniﬁcantly  more  frequent  mobility  problems.  Only  10%  of
L  patients  reported  cough  and  sputum  production  corre-
ponding  to  the  deﬁnition  of  chronic  bronchitis,  and  38%  had
yspnoea  (MRC  grade  I).
Table  3  shows  the  factors  independently  associated  with
L.  After  adjustment  for  age,  gender  and  smoking,  the
dds  ratio  for  AL  was  4.18  (95%  CI  1.72—10.15,  P  =  0.002)
n  patients  with,  versus  without,  CVD.  Independent  deter-
inants  of  AL  among  patients  in  primary  prevention  of  CVD
ere  assessed.  The  age,  gender  and  Framingham  CHD  risk-
djusted  odds  ratio  for  AL  was  3.76  (95%  CI  1.33—10.57, =  0.012)  in  patients  with  cumulative  smoking  ≥  25  pack-
ears  compared  with  those  <  25  pack-years.
p
3FEV1/FVC < 0.70 and predicted FEV1 < 30% or predicted FEV1 < 50%
lus chronic respiratory failure).
iscussion
irﬂow  limitation  compatible  with  COPD  was  present  in  5.9%
f  the  patients  at  cardiovascular  risk  referred  to  the  car-
iovascular  prevention  unit,  and  in  4.3%  of  the  patients  in
rimary  prevention  of  CVD.  Almost  80%  of  AL  patients  exhib-
ted  a  mild  form  (stage  I)  and  more  than  one  in  every  two
atients  was  asymptomatic.  After  adjustment  for  age,  gen-
er  and  smoking,  patients  with  CVD  had  a  fourfold  higher
isk  of  AL  than  those  without  CVD.  In  the  primary  preven-
ion  population,  smoking  was  the  main  predictor  of  AL  after
djustment  for  age,  gender  and  cardiovascular  risk.  More
han  80%  of  patients  had  not  been  diagnosed  previously  (86%
n  the  whole  population  and  84%  in  the  subsample  in  primary
revention).
To  the  best  of  our  knowledge,  our  study  is  the  ﬁrst  to
ssess  the  prevalence  of  AL  compatible  with  COPD  across  the
ange  of  patients  referred  for  prevention  of  CVD,  including
ubjects  in  primary  prevention,  those  with  known  cardio-
ascular  risk  factors  and  people  with  a  history  of  CVD.  We
lso  chose  to  report  the  prevalence  of  patients  exhibiting
 normal  FEV1/FVC  ratio  but  a  history  of  COPD,  as  these
re  COPD  patients  (probably  improved  by  appropriate  dis-
ase  management  following  diagnosis),  and  thus  had  to  berevalence  of  COPD  has  been  reported  to  range  from  12  to
4%  among  patients  with  coronary  artery  disease  [12—15].
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Table  2  Main  characteristics  of  airﬂow  limitation  (AL)  and  non-AL  participants.
Patients without AL Patients with AL P
(n = 464) (n = 29)
Demographic
Men 269 (58) 25 (86) 0.003
Age (years) 57.2 ± 11.0 59.4 ± 12.4 0.309
Educational level < high school completion 193 (42) 12 (41) 0.959
Cardiovascular risk factor
Smoking status
Never 190 (41) 10 (34) 0.601
Past 194 (42) 12 (41)
Current 80 (17) 7 (24)
Smoking (in pack-years)
< 25 391 (85) 19 (65.5) 0.015
≥ 25 69 (15) 10 (34)
Diabetes 36 (8) 1 (3) 0.714
Antihypertensive drug treatment 116 (25) 10 (34) 0.256
Systolic blood pressure (mmHg) 135 ± 17 138 ± 15 0.316
Diastolic blood pressure (mmHg) 81 ± 9 82 ± 7 0.384
Lipid-lowering drug treatment 196 (42) 20 (69) 0.005
Statins 114 (25) 14 (48)
Fibrates 22 (5) 0 (0)
Other lipid-lowering drugs 60 (13) 6 (21)
Total cholesterol (mg/dL) 230 ± 50 210 ± 50 0.106
LDL-cholesterol (mg/dL) 140 ± 50 130 ± 40 0.226
HDL-cholesterol (mg/dL) 60 ± 20 60 ± 20 0.748
Triglycerides (mg/dL) 1.6 ± 1.6 1.2 ± 0.7 0.269
Body mass index (kg/m2) 26 ± 4.6 24.9 ± 4.1 0.254
C-reactive protein (mg/L) 2.9 ± 4.6 3.2 ± 5.3 0.768
Family history of premature myocardial infarctiona 27 (6) 2 (7) 0.685
Framingham CHD risk (hard event)b
< 10% 247 (56) 9 (32) 0.1031
10—20% 116 (26) 4 (14)
> 20% 44 (4) 5 (18)
Personal history of cardiovascular diseasec 37 (10) 10 (34) < 0.001
Respiratory characteristic
FEV1 (L)d 3.2 ± 0.8 2.9 ± 0.9 0.021
FEV1 (% predicted) 113 ± 17 95 ± 26 < 0.001
FEV1/FVCe 80 ± 5 64 ± 7 < 0.001
Cough or sputumf 41 (9) 3 (10) 0.736
Dyspnoea (MRC scale)g
Grade I 135 (46) 6 (38) 0.350
Grade II 127 (43) 7 (44)
Grade III 19 (6) 1 (6)
Grade IV 11 (4) 2 (12)
Grade V 1 (1) 0 (0)
EuroQol 5D scale
No problem in mobility 383 (94) 20 (83) 0.014
No problem in self care 419 (99) 26 (100) 0.999
No problem in usual activity 391 (93) 25 (93) 0.719
No pain or discomfort 221 (54) 11 (44) 0.472
No anxiety or depression 210 (50) 12 (46) 0.880
Visual analogue scaleh 73 ± 16 73 ± 18 0.865
Data are number (%) or mean ± SD. CHD: coronary heart disease; FEV1/FVC: forced expiratory volume in 1 s/forced vital capacity; HDL:
high-density lipoprotein; LDL: low-density lipoprotein.
a Family history of premature myocardial infarction, i.e. < 55 years for the father or < 65 years for the mother.
b Ten-year risk of hard CHD event according to the Framingham equation (chart using LDL-cholesterol categories) [25] in subjects without
any history of cardiovascular disease.
c Ischaemic heart disease, history of cerebrovascular disease, atherosclerosis in other arteries such as aorta, renal or lower limb arteries.
d Forced expiratory volume in 1 s.
e Forced vital capacity.
f For ≥ 3 months during the past 2 consecutive years.
g Medical Research Council scale [21].
h The best health state you can imagine is marked 100 and the worst health state you can imagine is marked 0.
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Table  3  Independent  determinants  of  airﬂow  limitation  (AL).
Odds  ratio [95%  Conﬁdence  interval]  P
Women  1.00
Men  3.55  [1.19—10.63]  0.023
Age  (per  1-year  increase) 1.01 [0.98—1.05] 0.559
Smoking  <  25  pack-years 1.00
Smoking  ≥  25  pack-years  2.15  [0.92—5.01]  0.076
Personal  history  of  cardiovascular  diseasea
No  1.00
Yes  4.18  [1.72—10.15]  0.002
Variables initially introduced in the multivariable logistic regression model were gender, age, smoking, lipid-lowering-drug treatment,
total cholesterol, Framingham coronary heart disease risk and personal history of cardiovascular disease.
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n  a  study  conducted  by  Soriano  et  al.  in  the  Balearic  Islands
Spain)  [13], the  prevalence  of  AL  was  17.5%  in  middle-aged
ubjects  without  CVD,  randomly  selected  from  the  general
opulation;  19.2%  in  subjects  with  CVD;  and  33.6%  in  a  group
f  hospital  patients  with  coronary  artery  disease.  Overall,
hese  prevalences  were  higher  than  in  our  study,  which
ould  probably  be  explained  by  the  much  lower  proportion
f  never  smokers  among  Spanish  people  (18%  in  the  Span-
sh  study  vs  41%  in  our  population).  In  the  French  working
eneral  population,  the  prevalence  of  AL  was  reported  to
ange  from  5.7  to  7.5%  in  two  recent  studies  [28,29].  We
ound  a  prevalence  of  5.9%,  which  is  close  to  these  results
ut  lower  than  would  have  been  expected  for  people  with
ardiovascular  risk  factors  [28,29].  This  relatively  low  preva-
ence  could  in  part  be  explained  by  the  low  proportion  of
ubjects  exposed  to  occupational  dusts  and  chemicals  (0.8%,
 =  4)  or  environmental  tobacco  smoke  (passive  exposure  to
igarette  smoke;  1%,  n  =  5)  (data  not  shown).  Maybe  more
mportantly,  the  mean  age  of  the  sample  (57.4  ±  11.1  years)
as  relatively  low,  whereas  COPD  is  a  disease  preferentially
eveloping  among  people  older  than  60  years  [30]. More-
ver,  the  level  of  cardiovascular  risk  of  our  population  was
ctually  relatively  low,  as  shown  by  the  Framingham  10-year
isk  of  CHD  [25], which  was  <  10%  for  54%  of  the  sample.  Here
gain,  the  relatively  young  age  of  the  population  could  be
nvolved,  as  increasing  age  is  a  risk  factor  for  CVD.
Surprisingly,  smoking  was  not  associated  with  AL  in  the
ultivariable  analysis  conducted  in  the  whole  population,
hereas  the  relationship  was  signiﬁcant  before  adjustment.
 ﬁrst  explanation  is  a  possible  lack  of  power  (the  adjusted
dds  ratio  was  very  close  to  the  signiﬁcance  level:  P  =  0.076).
oreover,  the  effect  of  smoking  on  AL  could  have  been  con-
ounded  by  the  association  between  AL  and  CVD  or  gender.
ndeed,  on  the  one  hand,  smoking  and  CVD  are  frequently
ssociated  (in  our  sample,  74%  of  patients  with  CVD  were
mokers  vs  only  58%  of  patients  without  CVD  [P  =  0.027]).  On
he  other  hand,  smoking  and  male  gender  are  also  frequently
ssociated  (in  our  sample,  70%  of  men  were  smokers  vs  only
4%  of  women  [P  <  0.001]).  Adjusting  for  gender  and  CVD
ook  partly  into  account  the  effect  of  smoking  on  AL.  In  a
imilar  way,  lipid-lowering  drug  treatment  was  signiﬁcantly
ssociated  with  AL  in  univariate  analysis,  but  this  associa-
ion  did  not  remain  after  adjustment  (in  particular  after  the
ntroduction  of  CVD  as  an  adjustment  covariate).  Given  that
d
l
t
aerosis in other arteries such as aorta, renal or lower limb arteries.
ll subjects  presenting  with  both  AL  and  CVD  were  treated
ith  a  lipid-lowering  drug,  CVD  carried  very  similar  informa-
ion  to  that  carried  by  lipid-lowering  drugs  in  our  database.
onsequently,  adjusting  for  CVD  removed  the  signiﬁcant  sta-
istical  link  observed  between  AL  and  lipid-lowering-drug
reatment  in  univariate  comparisons.
The  combination  of  COPD  with  CVD  is  known  to  be  associ-
ted  with  poorer  prognosis  [9—11]. Observational  data  have
uggested  that  slowing  down  COPD  progression  might  help
o  reduce  cardiovascular  morbidity  and  mortality,  which  are
hemselves  associated  with  more  severe  pulmonary  symp-
oms  [31]  and  COPD  exacerbation  [32]. Therefore,  there  is
 good  rationale  for  screening  COPD  in  order  to  manage  the
isease  as  soon  as  possible,  prevent  exacerbation,  and  thus,
educe  the  risk  of  cardiovascular  events.  The  increased  risk
f  AL  among  subjects  with  CVD  and  the  low  proportion  of
atients  with  respiratory  symptoms  among  those  with  AL,
mphasize  the  need  for  a  systematic  screening  of  AL  in  these
atients,  irrespective  of  their  smoking  status  or  respiratory
ymptoms.  Among  patients  without  CVD,  such  a  screening
ould  be  proposed  in  people  who  have  smoked  25  pack-years
r  more.Several  mechanisms  could  explain  the  association
etween  AL  and  CVD.  First,  the  two  diseases  share  sim-
lar  risk  factors  such  as  male  gender,  age  and  smoking.
 very  recent  study  showed  that  COPD  is  not  more  fre-
uent  among  hospital  patients  with  ischaemic  heart  disease
ompared  with  ‘control’  hospital  patients,  when  traditional
ardiovascular  risk  factors  are  neutralized  by  matching  cases
nd  controls  according  to  gender  and  age  and  adjusting  for
moking  and  other  traditional  cardiovascular  risk  factors.
he  authors  concluded  that  the  higher  prevalence  of  car-
iovascular  risk  factors  in  COPD  patients  could  explain  the
ften-reported  association  between  COPD  and  CVD  [33].
OPD-associated  systemic  inﬂammation  could  be  another
xplanation,  as  it  is  known  that  chronic  inﬂammatory  dis-
ases  are  often  associated  with  increased  cardiovascular
isk.  For  instance,  this  point  has  been  underlined  clearly
y  the  recent  recommendations  on  rheumatoid  arthritis  and
therosclerotic  CVD  [34]. Besides,  COPD  and  CVD  could  both
elong  to  the  so-called  ‘chronic  systemic  inﬂammatory  syn-
rome’  [35]. Finally,  COPD  is  associated  with  decreased  daily
ife  activity,  even  when  airﬂow  obstruction  is  only  mildly
o  moderately  impaired  [36]. Interestingly,  reduced  physical
ctivity  is  a  risk  factor  for  both  COPD  and  CVD  occurrence.
 risk  
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It  is  also  known  to  impair  the  prognosis  of  the  two  diseases
[37—39].
Limitations
A  limitation  of  the  study  is  the  lack  of  postbronchodilator
spirometry.  Indeed,  airﬂow  obstruction  was  deﬁned  accord-
ing  to  prebronchodilator  spirometry  results,  in  line  with
several  recent  epidemiological  studies  [28,29,40]. Given
that  salbutamol  is  associated  with  spontaneous  arrhythmias,
its  use  in  patients  at  cardiovascular  risk  after  a  stress  test
was  potentially  dangerous  [41]. Consequently,  asthma  could
not  be  differentiated  from  COPD  in  patients  with  altered
spirometry,  and,  for  this  reason,  known  asthmatic  subjects
were  excluded  from  the  analyses,  which  may  have  underes-
timated  the  prevalence  of  AL.
Conclusions
Among  people  attending  a  CVD  prevention  unit,  we  iden-
tiﬁed  two  groups  of  subjects  with  an  increased  probability
of  AL:  patients  with  CVD  and,  in  primary  prevention,  peo-
ple  smoking  25  pack-years  or  more.  As  COPD  is  frequently
asymptomatic  but  may  impair  cardiovascular  prognosis,
these  patients  should  be  systematically  screened  for  AL.
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